| Project/Area Number |
18K15817
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 53010:Gastroenterology-related
|
|---|
| Research Institution | The University of Tokushima |
|---|
Principal Investigator |
MIYOSHI Jinsei 徳島大学, 大学院医歯薬学研究部(医学系), 助教 (00814625)
|
|---|
| Project Period (FY) |
2018-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2019: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2018: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | miRNA / ESCC / exosome / biomarker / liquid biopsy / リキッドバイオプシー / バイオマーカー / miRNAパネル / エクソソーム / 多重ロジスティック回帰分析 / 食道扁平上皮癌 |
|---|
| Outline of Final Research Achievements |
We initially identified a panel of 18 most differentially expressed miRNAs from the RNA-Seq data and all were successfully validated in three independent in-silico datasets and 32 pairs of matched cancer and normal tissues. Remarkably, a combination panel of these 8 miRNAs could significantly discriminate ESCC patients from normal subjects in serum cohort. Next, we assessed and optimized a 8-miRNA panel with an impressive AUC value of 0.83.
|
| Academic Significance and Societal Importance of the Research Achievements |
我々のモデル式はスクリーニングマーカーとしての臨床応用に加え、術後や化学療法中のモニタリングマーカーとしても応用可能である。さらに、我々が同定したmiRNAパネルは治療標的にもなる。つまり、癌進展に関わる多数の遺伝子を同時に制御することができるmiRNAの特性を利用し、全く新たな創薬開発への応用が期待出来る。
|
